05 July 2015 | Analysis | By BioSpectrum Bureau
A Challenging Year
North China Pharmaceutical, China
Chairman: Mr Yang Haijing
Revenue: $1470 mn
Business: Manufacturer and distributor of bulk drug, vitamins and antibiotics
North China Pharmaceutical is engaged in the production and distribution of range of pharmaceutical products including penicillin, streptomycin, oxytetracycline, lincomycin, semi-synthetic penicillins, cephalosporins, and other antibiotics, as well as bulk drugs in China and internationally.
The company had a dip in the revenue from $1.9 billion in 2013 to $1.4 billion in 2014. Continuing with the slip, the company reported revenue of $460 million in the first quarter of 2015, declining by 27.19 percent from the previous year.
North China Pharmaceutical appointed Mr Yang Haijing as its new chairman of the board, replacing Mr Wang Sheping. Over the years, the company has invested on research and development projects and has been developing new products including Kasugamycin, Bleomycin, Amphotericin B, Lincomycin, Clindamycin, and Clindamycin phosphate, Norvancomycin, Mecobalamin and EPO.
North China Pharmaceutical is among the world's largest supplier of penicillin along with amoxicillin, streptomycin, cefradine.
Huamin, a subsidiary of North China Pharmaceutical Group, received a GMP certificate from the Medicines and Healthcare products Regulators Agency in the UK to sell its sterile powder for injection in the EU region.